121 – 130 of 133
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.
(
- Contribution to journal › Article
-
Mark
CSF biomarkers and clinical progression of Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Amyloid biomarkers in Alzheimer's disease.
(
- Contribution to journal › Scientific review
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study
(
- Contribution to journal › Article
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
- 2014
-
Mark
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3.
(
- Contribution to journal › Article